Trial Information

Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study

Material and Methods Patient selection Consecutive patients who require elective lung
resection for cancer at the University Hospital of Geneva will be screened for the presence
of risk factors for postoperative ALI or hydrostatic lung edema: age > 60 yrs, history of
chronic alcohol consumption (>60g/day), prior radiation or chemotherapy, cardiac
insufficiency (left ventricular ejection fraction < 40%, or a history of past acute heart
failure), coronary artery disease (history of myocardial infarct, Q wave on the ECG,
positive stress test or coronary angiogram), recent pneumonia (within 6 weeks of hospital
admission), reduced diffusion capacity for carbon monoxide (DLCO < 60% of predicted values)
and predicted postoperative lung perfusion of < 55% of total lung perfusion. Patients with
at least 3 risk factors for postoperative lung edema will be considered eligible for the
study. Patients undergoing pneumonectomy or presenting with intracardiac shunts, valvular
diseases or aortic abdominal aneurysm will all be excluded as these conditions preclude
valid measurements of extravascular lung water volumes. In addition, chronic treatment with
inhaled bronchodilators, a history of any adverse reaction to bronchodilators and liver or
kidney insufficiencies will be considered exclusion criteria.

This randomized double blind, cross-over study has been approved by the local university
hospital ethics committee and written informed consent has been obtained from all selected
patients.

The same team of pneumonologists, thoracic surgeons and anesthesiologists/intensive care
physicians will be involved in the perioperative medical management. In addition to
history and clinical examination, a standardized preoperative assessment includes chest
radiography, ECG, pulmonary function testing as well as computed tomography scans and
positron emission tomographies of the chest, abdomen and brain. Quantitative lung
perfusion/ventilation scanning, brain imaging, maximal aerobic capacity and myocardial
stress testing will be performed when appropriate in intermediate-to-high risk surgical
candidates.

Operative and anesthetic management Routinely, antimicrobial prophylaxis with cefazoline
will be administered for 24 hours and an epidural catheter was inserted at the 4th-5th or at
the 5th-6th vertebral interspace. Thoracic epidural anesthesia (TEA) will be initiated
preoperatively with the administration of bupivacaïne 0.25% and continued postoperatively
with a lower dosage (bupivacaine 0.1%) that was combined with opiates (fentanyl 2 mcg/ml).

Each patient will be equipped with a 4-French femoral artery catheter and an internal
jugular venous line that will be connected to a pulse contour cardiac output monitor
(PV2024L; Pulsion Medical Systems AG, Munich, Germany).

After anesthesia induction, a left sided double-lumen endotracheal tube will be inserted and
pressure support ventilation will be adjusted to optimize gas exchanges and minimize lung
hyperinflation with low tidal volume (5-6 ml/kg), high inspiratory oxygen fraction (50-80%)
and positive end expiratory pressure levels (PEEP, 4-12 cm H2O). Periodically, lung
recruitment maneuvers will also be performed to re-open alveolar collapsed areas. Anesthesia
will be maintained by infusing propofol targeted to achieve bispectral
electroencephalographic values between 40 and 60. Lung resection with systematic lymph node
dissection will be performed through an anterolateral muscle-sparing thoracotomy.

During surgery, intravenous crystalloids (Ringer-lactate solution) will be infused at a rate
of 2-3 ml/kg/h and blood losses will be compensated with colloids
(poly(0-2-hydroxy-ethyl)amidon, HAES 6%) and with red blood cell concentrates if the
hemoglobin levels decreased below 80-90 g/L. At the end of surgery, all patients will be
extubated in the operating theater after reversing the residual neuromuscular blockade with
anticholinesterase agents. An active physiotherapy program including incentive spirometry,
deep diaphragmatic breathing exercises and mobilization will be started in the
high-dependency care unit (HDU). A maximal fluid balance of 500 ml per day will be targeted
during the first 48 hours after surgery, by limiting fluid intakes including i.v.
crystalloids (glucose-saline 0.45% 1 ml/kg/h), i.v. colloids (1/1 compensation of fluid
losses through thoracic drains and oral beverages (500 ml on the day of surgery and
1’000-1’200 ml over the next two days).

Study design Within the first 36 hours after surgery, patients will received in random order
nebulized salbutamol and nebulized ipratropium bromide at 4 consecutive sessions conducted
at least 6 hours apart (figure 1). The treatment order will be generated from random number
tables by an independent observer and concealed in sealed envelopes. The investigators,
attending physicians and nurses will be blinded to the treatment group.

Over 10 minutes, either salbutamol (5 mg diluted in 5 ml normal saline) or ipratropium
bromide (0.5 mg diluted in 5 ml normal saline) will be administered via a Cirrus nebulizer
and a compressor (Wokingham, UK).

Measurements In addition to arterial blood sampling, complete sets of hemodynamic
measurements will be performed as shown in figure 1: (a) preoperatively, before and 30 min
after initiation of TEA, (b) 2 and 8 hours after surgery (postoperative day 0, [POD0]),
before and 30 min after administration of salbutamol or ipratropium (6 hours apart in random
order), (c) on the morning of the first postoperative day (POD1) on two consecutive sessions
(6 hours apart in random order), before and 30 min after administration of salbutamol or
ipratropium bromide.

Cardiac output (CO) and volumetric pulmonary variables will be obtained by the simple
transpulmonary indicator dilution technique. Three consecutive measurements with less than
10% variations will be averaged. A fifteen milliliters bolus of 0.9% saline at 4°C will be
injected through the central venous catheter into the right atrium and the change in
temperature will be measured with the femoral artery thermistor tipped catheter. Using the
mean transit time methods, intrathoracic blood volume, extravascular lung water and global
end-diastolic volume will be calculated and indexed for the patient body weight (ITBVI,
EVLWI and GEDVI, respectively). Heart rate (HR), stroke volume (SV) and maximal change in
arterial pressure will be determined by beat-to-beat analysis of the arterial pressure wave.
The systemic vascular resistance index (SVRI) will be calculated using standard formula. The
ratio of EVLWI to ITBVI will be calculated as an index reflecting the permeability of the
alveolar–capillary barrier.

Arterial oxygen pressure (PaO2 in mmHg) will be measured using a blood gas analyzer (ABL-510
analyzer, Radiometer, Copenhagen, Denmark) and will be related to the inspiratory O2
fraction to express the oxygenation index (PaO2/FIO2). In addition, chest radiograph scores
(number of quadrants with >50% involvement with an alveolar filling process) will be
recorded on POD0 (arrival in HDU) and POD1 (end of the study).

Outcomes The primary outcome measure will be a reduction in EVLWI within the first 24 hours
after lung surgery. Secondary outcomes will be the PaO2/FIO2 ratio, hemodynamic data and
radiological lung injury score.

Statistical analysis A sample size of 20 subjects provides the power (80%) to detect a 20%
difference in EVLWI for a two-sided significance level of  = 0.05; in a preliminary study,
we found a mean value of 9.1 ml/kg for EVLWI with a standard deviation (SD) of 2.2 ml/kg.

Results will be reported as M(SD), median (interquartile) or numbers (percentages). A p
value of < 0.05 was considered significant in all analyses. All data will be analyzed with
the SPSS statistical software (version 9.0, SPP, Chicago, IL). ANOVA for repeated
measurements will be used to compare baseline values (preoperative, POD0 and POD1) followed
by Bonferroni post-hoc tests. Paired and unpaired Student t tests will be used to assess and
to compare the effects of bronchodilators. Furthermore, the correlation between changes in
EVLWI, CI, ITBVI and PaO2/FIO2 will be analyzed by linear regression.